STOCK TITAN

MAIA Biotechnology (MAIA) Stock Price, News & Analysis

MAIA NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
67 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
-27.1% close of March 3, 2026
1-year change
-2.9% closing prices, November 14, 2025 to November 16, 2026
1-month change
-8.2% closing prices, October 16, 2026 to November 16, 2026

Company Description

MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company is advancing a telomere-targeting approach in oncology, with its work centered on patients with advanced non-small cell lung cancer (NSCLC) who have limited treatment options after becoming resistant to prior immunotherapy and chemotherapy.

MAIA’s lead investigational candidate is ateganosine (also referred to as THIO, 6‑thio‑dG or 6‑thio‑2’-deoxyguanosine), described as a first-in-class small molecule telomere-targeting agent. According to the company’s disclosures and clinical posters referenced in its SEC filings, ateganosine is being evaluated as a second or later line of treatment for NSCLC in patients who have progressed beyond standard-of-care checkpoint inhibitor regimens.

Scientific focus and mechanism

Ateganosine is characterized as a dual-mechanism therapy. It is a modified nucleotide that is selectively incorporated into cancer-cell telomeres by telomerase, an enzyme that plays a fundamental role in the survival of cancer cells and their resistance to current therapies. This incorporation induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death.

In addition to direct effects on telomeres, ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activate both innate (cGAS/STING) and adaptive (T-cell) immune responses. Company materials describe this as an integrated telomere-targeting plus immune-activation model. In advanced in vivo cancer models, sequential treatment with ateganosine followed by PD-(L)1 inhibitors has been associated with profound and persistent tumor regression and the induction of cancer type–specific immune memory.

Clinical development in NSCLC

MAIA is running a clinical program in advanced NSCLC built around ateganosine sequenced with immune checkpoint inhibitors. The company highlights two key trials:

  • THIO-101 Phase 2 trial: A multicenter, open-label, dose-finding Phase 2 study evaluating ateganosine followed by PD-(L)1 inhibition in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after a first-line regimen containing another checkpoint inhibitor and chemotherapy. The trial’s primary objectives include assessing safety and tolerability and evaluating clinical efficacy using Overall Response Rate as a primary endpoint. The expansion phase (Part C) focuses on third-line NSCLC patients resistant to prior checkpoint inhibitor and chemotherapy regimens.
  • THIO-104 Phase 3 trial: A multicenter, open-label, randomized Phase 3 pivotal trial in third-line advanced NSCLC. Patients who are resistant to checkpoint inhibitor and chemotherapy treatments are randomized to receive ateganosine sequenced with a checkpoint inhibitor versus investigator’s choice of chemotherapy. The trial is designed with two primary objectives: assessing clinical efficacy using median Overall Survival as the primary endpoint and evaluating the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor.

Company communications indicate that MAIA has obtained regulatory approvals to screen patients for THIO-104 in Taiwan, Turkey, select European Medicines Agency (EMA) countries, and Georgia, and that screening and enrollment are underway. MAIA has also reported enrollment of patients in the THIO-101 expansion phase in countries including Hungary, Poland, Turkey, Taiwan, and Romania.

Regulatory designations and positioning

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of NSCLC. MAIA states that this designation supports its strategy to pursue accelerated or commercial approval pathways as the program advances through mid- to late-stage clinical development. Company press releases filed as exhibits to Form 8-Ks also note that ateganosine has received FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma (HCC), and small cell lung cancer (SCLC), which the company views as potential additional oncology indications beyond NSCLC.

In its public statements, MAIA describes ateganosine as, to its knowledge, the only direct telomere-targeting anticancer agent currently in clinical development and characterizes it as the first drug in a new therapeutic class. The company emphasizes the unmet need in NSCLC patients without actionable mutations and in those who have become refractory to checkpoint inhibitors and chemotherapy, and frames telomere-targeting therapeutics as a potential new pathway for this hard-to-treat population.

Capital formation and insider participation

MAIA has used private placements to fund its clinical programs and working capital. An 8-K dated December 16, 2025 describes a Securities Purchase Agreement with accredited investors for common stock and warrants in a private placement, with the company indicating that net proceeds are intended to fund the starting cost for Step 1 of Part C of the THIO-101 Phase 2 trial and for working capital.

Company news releases furnished to the SEC highlight repeated participation by directors and officers in these financings and in open-market purchases of MAIA common stock. The company presents this insider buying as a sign of alignment and confidence in the ateganosine program and its clinical and commercial potential.

Engagement with the oncology community

MAIA regularly presents data and trial-in-progress updates at major oncology and immunotherapy conferences. According to its 8-K filings, the company has prepared and presented posters on THIO-101 and THIO-104 at meetings such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress. These posters, filed as exhibits to Form 8-Ks and referenced in press releases, describe ongoing enrollment, safety observations, and trial designs for ateganosine-based regimens in advanced NSCLC.

MAIA has also highlighted presentations by its leadership and scientific advisors at conferences focused on oncology research and innovation, including events in Romania. These communications underscore the company’s emphasis on expanding trial access across multiple countries and engaging investigators in regions where advanced NSCLC remains a significant clinical challenge.

Business focus

Within the broader category of research and development in biotechnology and the professional, scientific, and technical services sector, MAIA Biotechnology’s activities are concentrated on:

  • Clinical-stage development of ateganosine as a telomere-targeting anticancer agent.
  • Combination regimens in which ateganosine is administered prior to PD-(L)1 checkpoint inhibitors.
  • Later-line treatment settings in advanced NSCLC, particularly third-line patients resistant to prior checkpoint inhibitor and chemotherapy regimens.
  • Exploration of additional indications where Orphan Drug Designations have been granted, such as glioblastoma, HCC, and SCLC, as disclosed in company communications.

According to its SEC filings, MAIA also prepares investor and conference presentation materials that summarize its clinical strategy, regulatory designations, and trial progress. These materials are periodically filed as exhibits to Form 8-Ks and posted to the company’s website.

Risk profile and stage

MAIA Biotechnology remains a clinical-stage company, and ateganosine is described as an investigational therapy. All references in company communications and SEC filings emphasize that regulatory approvals have not yet been obtained for commercial use, and that ongoing Phase 2 and Phase 3 trials are intended to generate the safety and efficacy data required for potential approval in NSCLC and other indications. As with other clinical-stage biopharmaceutical companies, MAIA’s prospects are closely tied to clinical trial outcomes, regulatory interactions, and its ability to finance continued development.

Stock Performance

$1.03
+1.98%
+0.02
Pre-marketLast updated: November 17, 2026 at 08:50
-2.9%
Performance 1 year
$63.6M

MAIA Biotechnology (MAIA) closed at $1.01 on November 16, 2026. Over the past 12 months, the price has lost 2.9%.

See what a $1,000 investment in MAIA would be worth today

Average down calculator for MAIA

MAIA Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

MAIA Biotechnology has 10 recent news articles, with the latest published today. Of the recent coverage, 3 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial, management. View all MAIA news →

Insider Radar

Net Buyers
90-Day Summary
258,078
Shares Bought
0
Shares Sold
7
Transactions
Most Recent Transaction
Vitoc Vlad (Chief Executive Officer) bought 73,000 shares @ $1.37 on September 14, 2026

Insider buying activity at MAIA Biotechnology over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

MAIA Biotechnology reported operating income of -$24.3M in FY2025, and net income was -$22.4M. Diluted earnings per share stood at -$0.70. The company generated -$18.8M in operating cash flow. The current ratio was 1.66, measuring current assets divided by current liabilities.

-$22.4M
Net Income (FY2025)
-$18.8M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

YEAR
2026
2026 Clinical

100+ patient milestone

MAIA expects to exceed 100 randomized patients in the pivotal THIO-104 Phase 3 NSCLC trial by year-end 2026; impacts trial progress and regulatory timing.
DEC
31
December 31, 2026 Clinical

Target enrollment completion

Target to dose up to 100 patients by 2026-12-31 across 34 sites in 6 countries; pivotal THIO-104 enrollment milestone.
DEC
31
December 31, 2026 Clinical

Dose 100 patients

Target to dose the 100th patient in the THIO-104 Phase 3 trial by 2026-12-31; enrollment updates via company press releases.
DEC
31
December 31, 2026 Clinical

100 patients dosed

Target to have 100 THIO-104 NSCLC patients dosed by Dec 31, 2026; screening active across Spain, Portugal and other European/Taiwan sites.
YEAR
2027
2027 Clinical

Interim survival analysis

Interim survival analysis for pivotal Phase 3 THIO-104 expected in 2027; results could materially affect program valuation.
YEAR
2027
2027 Clinical

Interim Phase 3 readout

THIO-104 interim readout for ateganosine in 3L NSCLC; global multicenter trial of up to 300 patients
YEAR
2027
2027 Clinical

Interim analysis

Targeted 2027 interim analysis for the THIO-104 Phase 3 trial; timing depends on enrollment and data maturity; results webcast.
JUL
20
July 20, 2027 - January 20, 2028 Regulatory

Potential early approval window

Company projects an 18–24 month path toward possible early commercial approval
OCT
15
October 15, 2028 Financial

Warrant expiration

Expiration of warrants issued in private placement
DEC
18
December 18, 2028 Financial

Warrants expiration

Warrants expire three years from issuance; final expiry date Dec 18, 2028; $1.36 strike

MAIA Biotechnology has 10 upcoming scheduled events. The next event, "100+ patient milestone", is expected in 2026. 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the MAIA stock price.

Short Interest History

Last 12 Months

Short interest in MAIA Biotechnology (MAIA) currently stands at 2.5 million shares, down 2.8% from the previous reporting period, representing 4.7% of the float. Since November 2025, short interest has increased by 256.6%.

Days to Cover History

Last 12 Months

Days to cover for MAIA Biotechnology (MAIA) currently stands at 9.0 days, up 55.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 170.1%. Across the settlements charted above, it has ranged from 1.0 to 9.0 days.

MAIA Company Profile & Sector Positioning

MAIA Biotechnology (MAIA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing MAIA often look at related companies in the same sector, including PDS Biotechnology Corporation (PDSB), Acrivon Therapeutics, Inc. (ACRV), Cardiff Oncology, Inc. (CRDF), Milestone Pharmaceuticals Inc. (MIST), and Cognition Therapeutics, Inc. (CGTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MAIA's relative position within its industry.

Frequently Asked Questions

The current stock price of MAIA Biotechnology (MAIA) is $1.03 in pre-market trading as of November 17, 2026.

The market cap of MAIA Biotechnology (MAIA) is approximately $63.6M. Learn more about what market capitalization means .

The FY2025 net income of MAIA Biotechnology (MAIA) is -$22.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of MAIA Biotechnology (MAIA) is -$0.70 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of MAIA Biotechnology (MAIA) is -$18.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of MAIA Biotechnology (MAIA), current assets divided by current liabilities, was 1.66 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of MAIA Biotechnology (MAIA) is -$24.3M for FY2025, its most recent completed fiscal year. Learn about operating income.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Its lead investigational candidate, ateganosine (THIO), is a first-in-class telomere-targeting agent being evaluated in advanced non-small cell lung cancer (NSCLC), particularly in patients who have become resistant to prior checkpoint inhibitor and chemotherapy treatments.

Ateganosine (THIO, 6‑thio‑2’-deoxyguanosine) is described by MAIA as a first-in-class small molecule telomere-targeting anticancer agent. It is a modified nucleotide that is selectively incorporated into cancer-cell telomeres by telomerase, causing telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments also accumulate in cytosolic micronuclei and activate innate (cGAS/STING) and adaptive (T-cell) immune responses.

MAIA’s primary clinical focus is advanced non-small cell lung cancer (NSCLC), especially in second or later line settings where patients have progressed beyond standard-of-care checkpoint inhibitor regimens. Company communications also state that ateganosine has received U.S. FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma (HCC), and small cell lung cancer (SCLC), which MAIA views as additional potential oncology indications.

THIO-101 is a multicenter, open-label, dose-finding Phase 2 clinical trial evaluating ateganosine followed by PD-(L)1 inhibition in patients with advanced NSCLC who did not respond to or developed resistance after a first-line regimen containing another checkpoint inhibitor and chemotherapy. The trial’s primary objectives are to evaluate the safety and tolerability of ateganosine and to assess clinical efficacy using Overall Response Rate as the primary endpoint, with an expansion phase focused on third-line NSCLC patients.

THIO-104 is a multicenter, open-label, randomized Phase 3 pivotal trial of ateganosine sequenced with a checkpoint inhibitor in third-line advanced NSCLC. Patients resistant to prior checkpoint inhibitor and chemotherapy treatments are randomized 1:1 to receive ateganosine plus a checkpoint inhibitor or investigator’s choice of chemotherapy. The trial is designed to assess median Overall Survival as the primary efficacy endpoint and to evaluate the safety and tolerability of the combination regimen.

Yes. MAIA reports that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine for the treatment of non-small cell lung cancer (NSCLC). Company communications also indicate that ateganosine has received FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma (HCC), and small cell lung cancer (SCLC).

In MAIA’s clinical trials, ateganosine is administered sequentially before PD-(L)1 checkpoint inhibitors. The company’s materials describe a strategy in which low doses of ateganosine are given prior to agents such as cemiplimab (Libtayo) to enhance and prolong immune response in advanced NSCLC patients who were resistant to previous checkpoint inhibitor treatments and chemotherapy.

MAIA Biotechnology is a clinical-stage company. Its lead candidate, ateganosine, is being evaluated in an ongoing Phase 2 trial (THIO-101) and a Phase 3 pivotal trial (THIO-104) in advanced non-small cell lung cancer. The company has not reported regulatory approval for commercial use of ateganosine and describes it as an investigational therapy.

According to a Form 8-K dated December 16, 2025, MAIA entered into a Securities Purchase Agreement with accredited investors for a private placement of common stock and warrants. The company states that it intends to use the net proceeds from this private placement to fund the starting cost for Step 1 of Part C of the THIO-101 Phase 2 trial and for working capital. Additional company news releases note ongoing insider participation in financings and open-market share purchases.

MAIA regularly issues press releases and prepares posters for major oncology and immunotherapy conferences, such as SITC, AACR-NCI-EORTC, and ESMO. These materials, which include trial-in-progress updates, enrollment status, and study designs for THIO-101 and THIO-104, are often filed as exhibits to Form 8-Ks with the SEC and referenced in the company’s public communications.